Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Part1: Advanced B-cell Malignancies 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Immune System Diseases 1COVID-19 1

Interventions

sotrovimab 1bemcentinib 1acalabrutinib 1Specimen Handling 1Rabeprazole 1Blood Specimen Collection 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × COVID-19 × acalabrutinib × Clear all
NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

AstraZeneca

Phase 1 Completed
20 enrolled
Lymphoid

COVID-19, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡